Quintiles, a fully-integrated biopharmaceutical services company
offering clinical, commercial, consulting and capital solutions
worldwide, has officially opened its new phase I research facility at
Apollo Health City, Hyderabad.
Constructed in partnership with Apollo Hospitals Group, the new
facility will complement Quintiles existing phase I facilities to help
customers navigate complex early development challenges and make key
decisions. It will provide biopharma customers additional options to
complete integrated phase I programs across multiple geographies at
this pivotal stage in medical research.
Mr Eddie Caffrey, senior vice president and head of phase I research,
Quintiles, said, “Sponsors are under intense pressure to speed-up
the delivery of results, ethically, and without compromising patient
safety or quality of data. With this new, state-of-the-art, phase I
facility in Hyderabad, we will be better able to ally with customers by
providing access to large numbers of healthy volunteers for simple
studies, in parallel to more complex studies conducted by scientific
experts in Europe and the US.�
The team in Hyderabad will work to global standards and procedures and
will be connected to sites in London, Uppsala and Kansas through
Quintiles global data network to simplify study management for sponsors
and provide integrated information and perspective as early as possible
in the development process.
The 86-bed unit will evaluate compounds developed both in India and in
other countries. Data capture will be linked electronically to
Quintiles' phase I units in the UK, the US, and Sweden. Thirty two beds
are equipped with technically advanced diagnostic cardiology equipment
for TQT studies.
Dow, GVK identify lead molecule
![](/IMG/057/46057/shutterstock40488508.jpg)
US-based agricultural company, Dow AgroSciences has
identified a new lead molecule in partnership with GVK Biosciences (GVK
BIO). This newly identified lead compound has been selected for its
ability to address a key product goal in support of Dow AgroSciences'
growing agricultural chemicals business.
The discovery research agreement with GVK BIO began in May 2008 with
the goal of generating novel molecules for synthesis and testing as
fungicides and insecticides. The two companies have benefited from the
depth of expertise in medicinal chemistry and chemoinformatics at GVK
BIO in combination with Dow AgroSciences' agricultural chemical
capabilities.
“We are very pleased to reach this milestone with GVK BIO under this
collaborative discovery alliance. As we will invest in our strong
agricultural chemicals business, we are building partnerships with some
of the world's best research teams to discover creative new solutions
in crop protection,� said Dr Daniel R Kittle, vice president of
R&D, Dow AgroSciences.
“The collaboration validates GVK BIO's ability and leadership in
discovery programs and specifically our expertise in agro-chemical
research. We are delighted with the outcome of the lead molecule and
attribute it to the significant collaborative efforts of the GVK BIO
and Dow teams,� said Mr Manni Kantipudi, chief executive officer, GVK
Biosciences.
Ecron Acunova expands India operation
Ecron Acunova, a leading CRO with operations in India and Europe,
has announced the expansion of Mangalore Clinical Pharmacology
Unit to a 80-bed facility.
This expansion caters to the growing needs of global clients in
pharmacokinetic and pharmacodynamic studies. This takes total bed
capacity to 176 units across research centers at Mangalore, Manipal and
Bangalore.
Drug research at the center involves analyzing the activity of the drug
in plasma using spectroscopy. Speaking on the occasion, Dr Pai says, “I
commend the safe conduct of studies for Indian and global companies,
leveraging the scientific and clinical talent of India. It is
heartening to note that studies conducted at the center, got FDA
approval, leading to launch of drugs for HIV and cancer treatments.�
Mr DA Prasanna, chairman and managing director, Ecron Acunova, said,
“In a short period of five years, over 250 phase I studies and over 70
late phase studies have been conducted, making the company one of the
top three amongst nearly 100 CROs in India. The expansion of the
facility will help us to serve our clients at a faster pace.�